Astria Therapeutics (NASDAQ:ATXS) Given Buy Rating at HC Wainwright

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $16.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 168.01% from the stock’s previous close.

Several other equities research analysts also recently weighed in on the stock. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Oppenheimer increased their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Finally, JMP Securities assumed coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They issued an “outperform” rating and a $26.00 price objective on the stock. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $25.67.

Astria Therapeutics Stock Up 2.6 %

NASDAQ ATXS traded up $0.15 on Tuesday, reaching $5.97. The stock had a trading volume of 121,085 shares, compared to its average volume of 260,975. Astria Therapeutics has a 12-month low of $5.73 and a 12-month high of $16.90. The stock has a fifty day moving average price of $7.32 and a two-hundred day moving average price of $9.65. The firm has a market capitalization of $336.91 million, a price-to-earnings ratio of -2.85 and a beta of 0.69.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01. Sell-side analysts forecast that Astria Therapeutics will post -1.65 earnings per share for the current fiscal year.

Institutional Trading of Astria Therapeutics

A number of hedge funds have recently bought and sold shares of the company. KLP Kapitalforvaltning AS acquired a new position in Astria Therapeutics in the 4th quarter valued at $41,000. Tower Research Capital LLC TRC increased its stake in Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 2,766 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in Astria Therapeutics during the fourth quarter worth about $50,000. Virtus ETF Advisers LLC purchased a new position in Astria Therapeutics during the fourth quarter worth about $65,000. Finally, Teacher Retirement System of Texas acquired a new stake in Astria Therapeutics in the 4th quarter worth about $91,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.